The Senate Health Committee recently cleared a bill that would allow generic drug manufacturers to enter the multi-billion dollar biological-drug market. The measure, which next heads to the full Senate for a vote, would clear the way for these drugs by requiring the Food and Drug Administration to create an approval process for follow-on biologics. […]
Bryan A. Liang
Bryan A. Liang is executive director of the Institute of Health Law Studies at California Western School of Law; the co-director of the San Diego Center for Patient Safety at UCSD School of Medicine; and a member of the Center for Public Health Security at San Diego State University.